Advertisement

Topics

PubMed Journals Articles About "Statin Therapy Reduces Risk Diabetic Retinopathy T2DM" RSS

21:32 EDT 18th March 2019 | BioPortfolio

Statin Therapy Reduces Risk Diabetic Retinopathy T2DM PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Statin Therapy Reduces Risk Diabetic Retinopathy T2DM articles that have been published worldwide.

More Information about "Statin Therapy Reduces Risk Diabetic Retinopathy T2DM" on BioPortfolio

We have published hundreds of Statin Therapy Reduces Risk Diabetic Retinopathy T2DM news stories on BioPortfolio along with dozens of Statin Therapy Reduces Risk Diabetic Retinopathy T2DM Clinical Trials and PubMed Articles about Statin Therapy Reduces Risk Diabetic Retinopathy T2DM for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Statin Therapy Reduces Risk Diabetic Retinopathy T2DM Companies in our database. You can also find out about relevant Statin Therapy Reduces Risk Diabetic Retinopathy T2DM Drugs and Medications on this site too.

Showing "Statin Therapy Reduces Risk Diabetic Retinopathy T2DM" PubMed Articles 1–25 of 30,000+

Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus.

We aimed to investigate whether there are differences in the risk factors or markers for the progression of diabetic retinopathy (DR) and diabetic nephropathy (DN) in type 2 diabetes mellitus (T2DM).


Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records.

Observations from statin clinical trials and from Mendelian randomization studies suggest that low low-density lipoprotein cholesterol (LDL-C) concentrations may be associated with increased risk of type 2 diabetes mellitus (T2DM). Despite the findings from statin clinical trials and genetic studies, there is little direct evidence implicating low LDL-C concentrations in increased risk of T2DM.

Development of diabetic retinopathy after cataract surgery.

This study explored whether cataract surgery precipitates diabetic retinopathy (DR) development in diabetic patients without previous DR. Patients with the diagnosis of type II diabetes but without DR were selected from the Longitudinal Health Insurance Database 2000. Patients who received cataract surgery between January 1, 2000, and December 31, 2010, were included in the case group, and the control group was matched to the case group by age, sex, and index year. The postoperative incidence rates of nonpr...


Telemedicine and diabetic retinopathy.

Diabetic retinopathy is prevalent among American adults with diabetes. Tight control of glycemic levels, BP, and lipids can help reduce patients' risk of developing diabetic retinopathy, which can lead to severe visual loss and blindness if not treated. Teleophthalmology done in primary care offices can increase the number of patients who are screened, saving patients' vision through early detection and treatment of diabetic retinopathy.

Predicting diabetic retinopathy and identifying interpretable biomedical features using machine learning algorithms.

The risk factors of diabetic retinopathy (DR) were investigated extensively in the past studies, but it remains unknown which risk factors were more associated with the DR than others. If we can detect the DR related risk factors more accurately, we can then exercise early prevention strategies for diabetic retinopathy in the most high-risk population. The purpose of this study is to build a prediction model for the DR in type 2 diabetes mellitus using data mining techniques including the support vector mac...

Statin Intolerance.

Statins are critical medications to prevent and treat cardiovascular disease and they are generally very well tolerated. In some instances, however, statin intolerance may limit use of these lifesaving medications. Statin intolerance has many definitions but is commonly diagnosed when a patient is unable to continue statin therapy due to perceived, or objectively documented, adverse effects. A very high rate of discontinuation of statin therapy warrants a closer look at the implications from the standpoint ...

Longitudinal relationship between retinal diabetic neurodegeneration and progression of diabetic retinopathy in patients with type 2 diabetes.

To investigate the longitudinal relationship between diabetic retinal neurodegeneration and the progression of diabetic retinopathy (DR) by measuring macular ganglion cell-inner plexiform layer (mGCIPL) thickness in patients with type 2 diabetes (T2DM).

2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.

Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there i...

Short-Term Impact of Bariatric Surgery on Best-Corrected Distance Visual Acuity and Diabetic Retinopathy Progression.

The immediate impact of rapid glucose lowering induced by bariatric surgery on diabetic retinopathy (DR) progression remains unclear. We present 3-year changes in the best-corrected visual acuity and DR grade in a retrospective observational study of 32 morbidly obese patients (64 eyes) who underwent Roux-en-Y-gastric bypass surgery. We found that despite overall benefits in vision, there was an initial progression from no retinopathy to background retinopathy in 18.9% and 21.7% at years 1 and 2 respectivel...

The emerging concept of "individualized cholesterol-lowering therapy": A change in paradigm.

High LDL-cholesterol concentrations constitute a risk for atherosclerotic cardiovascular disease. By consensus, cholesterol-lowering therapy is initiated with a statin that reduces endogenous cholesterol synthesis, upregulates hepatic LDL receptor activity, increases LDL clearance and lowers LDL-cholesterol concentrations in the bloodstream. The efficacy of statin treatment is dose dependent and achieves a risk reduction of up to 50%. However, a substantial body of evidence suggests that a quarter of statin...

CETP inhibition, statins and diabetes.

Type 2 diabetes is a causal risk factor for the development of atherosclerotic cardiovascular disease (ASCVD). While treatment with a statin reduces the risk of having an ASCVD event in all people, including those with type-2 diabetes, statin treatment also increases the likelihood of new onset diabetes when given to those with risk factors for developing diabetes. Treatment with the cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, reduces the risk of having a coronary event over and above ...

Single herbal medicine for diabetic retinopathy.

Diabetic retinopathy is one of the major causes of blindness and the number of cases has risen in recent years. Herbal medicine has been used to treat diabetes and its complications including diabetic retinopathy for thousands of years around the world. However, common practice is not always evidence-based. Evidence is needed to help people with diabetic retinopathy or doctors to make judicious judgements about using herbal medicine as treatment.

Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy.

To determine the risk factors for retinal microvascular impairment on optical coherence tomography angiography (OCT-A) in type 2 diabetic patients without clinical diabetic retinopathy (DR).

Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials.

To explore the accumulated evidence concerning the effect of intensive blood pressure control on the incidence and progression of diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and macular edema (ME).

Anti-VEGF Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions.

To illustrate that patients with diabetic retinopathy who are treated exclusively with anti-VEGF therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences.

Association of serum inflammatory markers and diabetic retinopathy: a review of literature.

Diabetic retinopathy is the leading cause of irreversible blindness in the western world, among the working-age people. Its exact pathogenesis, however, remains obscure. Systemic inflammation is regarded to play a significant role in diabetes by contributing, among others, to the development of diabetic retinopathy. This review focuses on the possible involvement of the systemic inflammatory markers in the pathogenesis of diabetic retinopathy.

Diabetic retinopathy techniques in retinal images: A review.

The diabetic retinopathy is the main reason of vision loss in people. Medical experts recognize some clinical, geometrical and haemodynamic features of diabetic retinopathy. These features include the blood vessel area, exudates, microaneurysm, hemorrhages and neovascularization, etc. In Computer Aided Diagnosis (CAD) systems, these features are detected in fundus images using computer vision techniques. In this paper, we review the methods of low, middle and high level vision for automatic detection and cl...

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies.

To evaluate durability of diabetic retinopathy (DR) improvements after a change in ranibizumab dosing from monthly to individualized pro re nata (PRN) therapy.

Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.

Present rationale, guidelines, and results of ranibizumab treatment for proliferative diabetic retinopathy (PDR) in Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S.

The prevalence and risk factors of diabetic retinopathy in selected primary care centers during the 3-year screening intervals.

This study aimed to determine the prevalence and progression of diabetic retinopathy (DR) and its risk factors in patients with diabetes attending primary care centers.

Six-year incidence and progression of diabetic retinopathy in Indian adults: the Singapore Indian Eye study.

Diabetes is a major public health problem in migrants and ethnic minorities worldwide. We determined the incidence and risk factors of diabetic retinopathy (DR) in migrant Indians living in Singapore.

Disorganization of Retinal Inner Layers (DRIL) and Neuroretinal Dysfunction in Early Diabetic Retinopathy.

To elucidate the relationship between disorganization of retinal inner layers (DRILs) and retinal function in diabetic patients without diabetic retinopathy (DR) and with nonproliferative DR, but without diabetic macular edema (DME).

Should all diabetic patients take statin therapy regardless of serum cholesterol level?

Diabetic Retinopathy in Hispanics: A Perspective on Disease Burden.

To describe how the United States Hispanic population is affected by diabetic retinopathy (DR) and to identify existing barriers to screening and care.

Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.

Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM). Urate-lowering therapy (ULT) might be beneficial in lowering the risks of T2DM. Therefore, we conducted a nested case-control study to evaluate the associations between ULT and T2DM.


Advertisement
Quick Search
Advertisement
Advertisement